Growth inhibition of ovarian tumor-initiating cells by niclosamide

Yi Te Yo, Ya Wen Lin, Yu Chi Wang, Curt Balch, Rui Lan Huang, Michael W.Y. Chan, Huey Kang Sytwu, Chi Kuan Chen, Cheng Chang Chang, Kenneth P. Nephew, Tim Huang, Mu Hsien Yu, Hung Cheng Lai

Producción científica: Articlerevisión exhaustiva

107 Citas (Scopus)


A recent hypothesis for cancer chemoresistance posits that cytotoxic survival of a subpopulation of tumor progenitors drives the propagation of recurrent disease, underscoring the need for new therapeutics that target such primitive cells. To discover such novel compounds active against drug-resistant ovarian cancer, we identified a subset of chemoresistant ovarian tumor cells fulfilling current definitions of cancer-initiating cells from cell lines and patient tumors using multiple stemness phenotypes, including the expression of stem cell markers, membrane dye efflux, sphere formation, potent tumorigenicity, and serial tumor propagation. We then subjected such stem-like ovarian tumor-initiating cells (OTIC) to high-throughput drug screening using more than 1,200 clinically approved drugs. Of 61 potential compounds preliminarily identified, more stringent assessments showed that the antihelmintic niclosamide selectively targets OTICs in vitro and in vivo. Gene expression arrays following OTIC treatment revealed niclosamide to disrupt multiple metabolic pathways affecting biogenetics, biogenesis, and redox regulation. These studies support niclosamide as a promising therapy for ovarian cancer and warrant further preclinical and clinical evaluation of this safe, clinically proven drug for the management of this devastating gynecologic malignancy.

Idioma originalEnglish (US)
Páginas (desde-hasta)1703-1712
Número de páginas10
PublicaciónMolecular cancer therapeutics
EstadoPublished - ago 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Profundice en los temas de investigación de 'Growth inhibition of ovarian tumor-initiating cells by niclosamide'. En conjunto forman una huella única.

Citar esto